Vertex Pharmaceuticals Inc

NASDAQ: VRTX
$499.88
+$27.08 (+5.7%)
Closing Price on November 5, 2024

VRTX Stock Chart and Intraday Price

VRTX Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 50 NORTHERN AVENUE, BOSTON, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 111,785.37M USD
Shares Outstanding 258,308,000
Vertex Pharmaceuticals Inc is a pioneering biotechnology firm focused on creating innovative treatments for cystic fibrosis (CF) and other serious diseases. It offers a range of CF therapies, including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, targeting different age groups and genetic mutations. Beyond CF, Vertex is exploring treatments for pain, sickle cell disease, beta thalassemia, and Type 1 Diabetes through advanced clinical trials. Founded in 1989 and based in Boston, Massachusetts, Vertex collaborates with leading biotech entities to expand its therapeutic portfolio, aiming to address unmet medical needs.

VRTX Articles

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices. Walmart (NYSE:WMT) split its stock in February,...
Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which I’m going to dive into with a few of these picks. Whether we’re...
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
There has been a noticeable shift in the stock market over the last two months. Investors are moving away from former high-flying large- and mega-cap stocks into discounted small-cap names that the...
The tech stock selloff in July surprised the market but not those investors who were paying attention. As far back as April, Goldman Sachs (NYSE:GS) warned of the coming decline. Its analysts said...
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re...
Wednesday's top analyst upgrades and downgrades included Abbott Laboratories, Boston Scientific, ChargePoint, Coinbase Global, Dollar General, Equitrans Midstream, Ford, Hasbro, Johnson & Johnson,...
Friday's top analyst upgrades and downgrades included Builders FirstSource, CVS Health, DHT, Incyte, McDonald's, Newell Brands, PacWest Bancorp, Wingstop and ZoomInfo Technologies.
Wednesday's top analyst upgrades and downgrades included BP, ConocoPhillips, Equity Residential, Exxon Mobil, Global Payments, Kroger, Microsoft, NRG Energy, RingCentral, Valero Energy, Wayfair,...
Tuesday's top analyst upgrades and downgrades included AT&T, Baxter International, Centene, Darden Restaurants, Lennar, L3 Harris Technologies, MGM Resorts International, Nvidia and Vertex...
Thursday's top analyst upgrades and downgrades included Analog Devices, Aptiv, CF Industries, Ford, Mosaic, Park Hotels & Resorts, Patterson-UTI Energy, Pinterest, Plug Power, Salesforce, Snap,...
Wednesday's top analyst upgrades and downgrades included Allbirds, Amazon.com, American Eagle Outfitters, Canopy Growth, Citizens Financial, Cleveland-Cliffs, Etsy, Deere, LyondellBasell Industries,...
Monday's top analyst upgrades and downgrades included Bill.com, Block, Cigna, Crocs, CommScope, Dish Network, Foot Locker, Gap, Graphic Packaging, Ingersoll Rand, Moderna, Penn National Gaming,...
Tuesday's top analyst upgrades and downgrades included Amgen, Array Technologies, Boeing, Carvana, DocuSign, Enterprise Products Partners, Fiserv, Johnson Controls, Monster Beverage, Nvidia, PayPal,...
Tuesday's top analyst upgrades and downgrades included Analog Devices, Baxter, BorgWarner, Caesars Entertainment, CarMax, Chevron, Hertz Global, Li Auto, Starbucks, Tesla and Twitter.